Oncology Experts Review Key ASCO 2026 Data for Daraxonrasib and Other Novel Therapies in GI Cancers

The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.

The FDA has approved lirafugratinib (Lyrfigtu) for the treatment of adult patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.

Lanreotide injection, a generic formulation referencing lanreotide, was approved by the FDA for GEP-NETs management.

The FDA granted final approval to aLutetium Lu 177 dotatate biosimilar for patients with SSTR-positive GEP-NETs.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A marketing authorization application for lirafugratinib in previously treated FGFR2-altered metastatic cholangiocarcinoma has been submitted to the EMA.

Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.

Daraxonrasib plus gemcitabine and nab-paclitaxel received FDA breakthrough therapy designation for treatment-naive metastatic pancreatic adenocarcinoma.